[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_95":96},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","rqv3hgm75qju0eqrmampi8qmq","revision",2,"title","Alterity Therapeutics 提交 6-K 文件，列出 ATH434 的 MSA 二期数据新分析演示","originalTitle","6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)","summary","Alterity Therapeutics 提交 6-K 文件，将该文件纳入其 Form S-8 和 Form F-3 注册声明。文件所列附件 99.1 为公司展示 ATH434 的 MSA 二期数据新分析。","reason","source",{"_11":85,"_86":87,"_88":89,"_90":57,"_91":92,"_93":94},"links",{"_82":83,"_63":84},"publishedAt","2026-10-05T10:01:03.000Z","discoveredAt","2026-10-05T10:48:13.183Z","timelineAt","category","ai-products","tags",[80,81],"stockSymbols",[],"score",25,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fakt-ixOON_g",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","c566b93b-bf30-443d-a052-da7ca7a9ac4c","Alterity提交6-K并披露ATH434分析",{"_72":73,"_15":74},"zh","

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (File No. 333-274816)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

99.1

\n\t\t\t

Alterity Presents New Analyses of ATH434 Phase 2 Data in MSA

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

	\n\t\t\t Alterity Therapeutics Limited \n\t\t\t

	\n\t\t\t By: \n\t\t\t	\n\t\t\t /s/ Julian Babarczy \n\t\t\t
		\n\t\t\t Julian Babarczy \n\t\t\t
		\n\t\t\t Chairman \n\t\t\t

Date: October 5, 2026

","zhKind","complete","公司与财报","AI","aihot","/items/rqv3hgm75qju0eqrmampi8qmq","https://www.sec.gov/Archives/edgar/data/1131343/000143774926031946/0001437749-26-031946-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791417600&sig=18cddd50281c55e6","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791417600&sig=6c66a0408e1695ad 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791417600&sig=11363acd4f484981 96w","changelogVersion","2026-10-01T08:00"]